When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...
Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback